"Janus Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains.
| Descriptor ID |
D053612
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124 D12.776.476.393
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinases".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinases".
This graph shows the total number of publications written about "Janus Kinases" by people in this website by year, and whether "Janus Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 0 | 2 |
| 2012 | 6 | 3 | 9 |
| 2013 | 5 | 4 | 9 |
| 2014 | 3 | 3 | 6 |
| 2015 | 3 | 8 | 11 |
| 2016 | 2 | 7 | 9 |
| 2017 | 5 | 7 | 12 |
| 2018 | 3 | 5 | 8 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 2 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinases" by people in Profiles.
-
JAK/STAT defects and immune dysregulation, and guiding therapeutic choices. Immunol Rev. 2024 Mar; 322(1):311-328.
-
Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation. Leuk Lymphoma. 2023 10; 64(10):1662-1672.
-
Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression. Blood Adv. 2023 03 14; 7(5):712-717.
-
Adenoviral gene therapy for bladder cancer. Cell. 2023 03 02; 186(5):893.
-
Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice. Cancer Res. 2022 03 15; 82(6):1098-1109.
-
Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nat Genet. 2022 02; 54(2):170-179.
-
Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.
-
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2022 Jan; 101(1):131-137.
-
Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia. 2021 12; 35(12):3361-3363.
-
Cellular and Molecular Mechanisms of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2021 01 01; 147(1):30e-41e.